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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• HIV-1 co-infection with HBV/HCV is the
most important factor determining
efavirenz-induced liver toxicity. Higher
efavirenz plasma concentrations have been
reported in these patients facilitating
concentration drug-related adverse effects.
• It is not known whether changes in
efavirenz disposition are due to the
hepatitis infection/inflammation or to liver
failure. As a consequence, the guidelines for
the application of therapeutic drug
monitoring of efavirenz in HBV/HCV
co-infected patients have not been
established.
WHAT THIS STUDY ADDS
• The present study has shown that HBV/HCV
infection in itself does not predispose to
higher efavirenz plasma concentrations. In
the absence of hepatic failure, the risk of
efavirenz concentration-dependent toxicity
is not increased.
• Thus, therapeutic drug monitoring
indications in co-infected patients with
hepatic function within the normal range
should be the same as in HIV-1
mono-infected patients.
AIMS
Data on efavirenz in HIV/viral hepatitis co-infected patients is
non-consensual, probably due to liver function heterogeneity in the
patients included.
METHODS
A case control study was performed on 27 HIV-infected patients, with
controlled and homogenous markers of hepatic function, either
mono-infected or co-infected with HBV/HCV, to ascertain the influence
of viral hepatitis on efavirenz concentrations over a 2-year follow-up
period.
RESULTS
No differences were found in efavirenz concentrations between groups
both during and at the end of the follow-up period: control
(2.43 1.91 mg l–1) vs. co-infected individuals (2.37 0.37 mg l–1).
CONCLUSION
It was concluded that HBV/HCV infections in themselves do not
predispose to an overexposure to efavirenz.
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Introduction
Chronic viral hepatitis by-hepatitis B virus (HBV) and hepa-
titis C virus (HCV) is common among people with human
immunodeficiency virus (HIV-1) infection because of
shared modes of transmission [1–3] and has been largely
responsible for end-stage liver disease [4]. Hepatic disease
can reduce the clearance of drugs that are metabolized by
the liver, increasing the risk of dose-related toxicities.
Efavirenz is a non-nucleoside reverse transcriptase
inhibitor extensively metabolized to inactive hydroxylated
metabolites by the cytochrome P450 enzymatic system,
with subsequent urinary and biliary excretion of these
metabolites after glucuronidation [5]. Exposure to high
efavirenz plasma concentrations has been associated
with an increased risk of experiencing neuropsychiatric
adverse events [6–8]. Liver toxicity (severe increase in liver
enzymes) related to efavirenz occurs in 1 to 8% of patients
[9] and has been attributed to hypersensitivity reactions
to efavirenz [10, 11] or to an accumulation or dose-
dependent mechanisms [12].
HBV/HCV co-infection is the most important factor
associated with efavirenz-induced liver toxicity [13–15]
but it is not known what the contribution of infection/
inflammation by hepatitis virus is to efavirenz disposition.
Data on efavirenz plasma concentrations in HBV/HCV
co-infected patients is scant and contradictory and most of
the data corresponds exclusively to one sample measure-
ment per patient. Some reports, without data on hepatic
liver function [8, 16] or with ‘normal’ liver function tests
[17], show indirect indications that HBV/HCV infection
does not necessarily predispose to higher efavirenz
plasma concentrations in co-infected patients. However,
association with high efavirenz plasma concentrations and
cirrhosis or elevated hepatic enzymes was found in HBV/
HCV co-infected patients [18–21].
In the present work a case control study was
performed by monitoring efavirenz concentrations in
HBV/HCV co-infected patients with controlled hepatic
function, during 24 months in order to know whether the
presence of HBV/HCV co-infection per se does influence
plasma concentrations of efavirenz in the absence of
severe hepatic damage.
Methods
All eligible patients were adults on efavirenz-containing
regimens either as or not as initial therapy. The protocol
received prior approval from the Hospital Ethics Commit-
tee, patients gave their written informed consent and
adherence was controlled through a questionnaire.
Patients on concomitant medication other than antiret-
roviral drugs were also included. Only one patient was
treated for HCV with pegylated-interferon combined with
ribavirin in the second half of the study. No adjustments in
efavirenz dose were made throughout the study.
Efavirenz determinations and blood collecting time
were performed as previously described [22].
The assessment of the liver function was based on the
analysis of key biochemical markers in hepatic systems and
function [23]: markers of hepatocellular integrity (alanine
aminotransferase (ALT) and aspartate aminotrans-
ferase (AST)); cholestasis (alkaline phosphatase (AP);
g-glutamyltranspeptidase (GGT); total bilirubin and direct
bilirubin) and liver function (prothrombine international
normalized ratio (PT) and albumin).The AST : ALT ratio was
also recorded as a non-invasive method to differentiate the
various degrees of hepatic disease severity: an AST : ALT
ratio <1 has been associated with chronic hepatitis fibrosis
score 0–3; an AST : ALT ratio 1 and <1.5 is common in
patients with chronic hepatitis fibrosis score 4; and an
AST : ALT ratio1.5 means cirrhosis Child-Pugh class B and
C [24].
Results were shown as mean  SEM. Differences
between groups were compared with Student’s t-test.
GraphPad Prism version 4 was used to perform analysis.
Results
This study was conducted in 27 HIV-infected patients on
efavirenz (600 mg once daily) for more than 1 month: 18
were negative for HBV and HCV (control group) and nine
were positive for HBV (n = 2) or HCV (n = 7) positive (study
group).
The characteristics of the patients included in both
groups were similar. The control group included 14 males
and four females, aged 43 3 years and with a body mass
index (BMI) of 23 3 kg m–2. These patients were on
efavirenz for 14 3 months, 57% were on efavirenz plus
zidovudine and lamivudine and 10 patients were on their
first antiretroviral regimen. The patients (seven males and
two females) included in the study group were aged
39 3 years and had a mean BMI of 23 3 kg m–2. These
patients were on efavirenz for 20 3 months,67% were on
efavirenz plus zidovudine plus lamivudine and three
patients were on their first antiretroviral regimen.
The CD4+ cell count at baseline was not different
between the mono-infected (504 66 cell mm-3) and the
co-infected group (401 32 cell mm-3). In both groups
more than 70% of the patients had viral load <50
copies · mL–1.
At the baseline, no differences between groups in
hepatocyte integrity and cholestasis were found (Table 1).
Liver mass markers were similar between groups: baseline
albumin mean value was 4.0 0.1 g dl–1 in both groups
(reference range 3.4–4.8 g dl–1) and the baseline PT was
1.04 0.06 in the mono-infected group and 1.02 0.04 in
the co-infected group.
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Inter-individual variability in efavirenz plasma concen-
trations, calculated as coefficient of variation was 45% for
the control group and 53% for the co-infected group.
At the end of the follow-up, no differences were found
in the markers of hepatic function between mono-infected
and co-infected patients. Although at month 24, increases
in bilirubin (direct and total), in both mono- and
co-infected patients (Table 1), were observed.
The efavirenz concentrations (Figure 1), at the baseline
were higher (p = 0.036) in mono-infected individuals
(1.86 0.16 mg l–1) than in co-infected individuals
(1.56 0.93 mg l–1). However, efavirenz concentrations
remained within the therapeutic range (1–4 mg l–1) [6],
similar in both case and control groups during the
follow-up and no differences were observed in intra-
individual variability between the control (27 18%) and
co-infected group (37 14%).
Discussion
Changes in the hepatic drug metabolism of HIV patients
co-infected with HBV/HCV can be affected by both the
specific infection/inflammation caused by these viruses
and by the severity of liver disease.
In our knowledge, this is the first work to analyze
efavirenz concentrations in patients, with long-term con-
trolled and homogeneous characteristics of hepatic
function, without advanced stages of liver disease. It is con-
cluded that: the infection by itself did not modify efavirenz
concentrations; that the risk of efavirenz concentration-
dependent toxicity is not increased in co-infected patients
with normal hepatic function and that therapeutic drug
monitoring (TDM) indications for these co-infected
patients and HIV mono-infected patients are the same.
The 2 years of follow-up contributes to minimizing the
limitation of the small number of patients included. This
pilot study contributed to surpass the lack of information
in the literature, not only about the true difference in
efavirenz plasma concentrations between the mono and
Table 1
Comparison of hepatocellular integrity and cholestasis markers between, study (HIV and HBV or HCV co-infected patients) and control (HIV mono-infected
patients) at the baseline and after 24 months of follow-up
Marker (Reference range) Study point
HIV mono-infected
(n = 18)
HBV or HCV co-infected
(n = 9) P value
AST
(<31 U l–1)
Baseline 27  3 35  4 NS
Month 24 24  2 36  7 NS
P value NS NS
ALT
(<31 U l–1)
Baseline 49  5 59  9 NS
Month 24 34  3 58  9 0.0297
P value 0.0222 NS
AST : ALT
(<1)
Baseline 0.56  0.04 0.71  0.16 NS
Month 24 0.85  0.12 0.68  0.04 NS
P value 0.0267 NS
AP
(35–104 U l–1)
Baseline 89  5 94  9 NS
Month 24 80  5 84  9 NS
P value NS NS
GGT
(<36 U l–1)
Baseline 67  13 114  31 NS
Month 24 55  10 140  44 NS
P value NS NS
Total bilirubin
(<1.00 mg l–1)
Baseline 0.31  0.04 0.37  0.06 NS
Month 24 0.52  0.07 0.57  0.13 NS
P value 0.0118 NS
Direct bilirubin
(<0.30 mg l–1)
Baseline 0.11  0.01 0.11  0.03 NS
Month 24 0.24  0.03 0.21  0.02 NS
P value 0.0002 0.0352
Data are expressed in mean  SEM. ns, non significant (p > 0.05). ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase. GGT:
g-glutamyltranspeptidase.
















Time course of plasma concentrations of efavirenz. The solid line repre-
sents plasma concentrations of HIV mono-infected patients (n = 18)
and the dotted line refers to plasma concentrations in HIV patients
co-infected with HBV or HCV (n = 9). Month 0 corresponds to the inclusion
of the patients in the study. Each point represents mean SEM. *p < 0.05
Student’s t-test
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the co-infected patients but also about the variability of
those measurements. It also generated data on within- and
between-subject variations that will allow sample size
calculation in further studies.
Recently the influence of liver fibrosis on efavirenz
plasma concentrations was reported [21]. In that study, no
functional data were analyzed and hepatic impairment
was assessed exclusively by quantifying fibrosis using elas-
tometry. This allowed authors to conclude that efavirenz
concentrations are significantly higher in cirrhotic patients.
This data fits with other previously described [18, 20] and,
as it occurs in general with drugs that undergo hepatic
elimination, cirrhosis increases efavirenz concentrations.
In the present work, we have looked into the hepatic
function of patients with no clinical indications to do liver
biopsies, particularly in those considered ‘well compen-
sated’, where the degree of fibrosis could not be precisely
discriminated by non-invasive methods.
The present work does not allow us to ascertain if
high GGT concentrations were due to virus infection or
to efavirenz, because at the baseline patients were on
efavirenz for at least 14 months. Increases in GGT have
been associated with HIV-infection [25] and efavirenz con-
centrations higher than 2.18 mg l–1, but only during the
firsts 6 weeks of treatment [12].
At month 24, the ALT was significantly lower in mono-
infected patients, although no changes in the AST/ALT or
other analytical markers were observed. It is known that
HCV-infection is characterized by a pattern of aminotrans-
ferase concentrations fluctuating around the upper refer-
ence value and elevated ALT values [26, 27].
It is known that hepatic drug clearance is depressed
by most viruses, including HIV [28]. The CYP3A4 and
CYP2D6 activities were significantly lower in patients with
chronic hepatitis than those observed in healthy volun-
teers [28]. Besides efavirenz being a substrate for CYP3A4
and CYP2B6, we did not find differences in efavirenz
concentrations.
The absence of toxic concentrations (>4 mg l–1, [6])
found in co-infected patients is consistent with the results
obtained by Gutierrez et al., who did not find that co-
infected patients are at a higher risk to neuropsychiatric
adverse events due to overexposure to efavirenz [8]. In
addition to normal efavirenz concentrations, hepatitis
co-infection by itself did not apparently modify either
intra- or inter-patient variability. The coefficients of varia-
tion herein observed in mono-infected patients were
lower than those previously described in more heteroge-
neous groups of patients, like those included in TDM
services. [6, 22, 29, 30].
No explanation for the lower efavirenz plasma concen-
trations observed in co-infected patients at baseline can
be proposed because, at that point, efavirenz steady state
concentrations have already been achieved and the diag-
nosis of hepatitis was performed simultaneously with HIV
infection.
The concentrations of direct and total bilirubin at the
end of the 24 months were higher than at baseline in both
the mono-infected and the co-infected patients. This was
an unexpected finding observed with drug concentrations
within the therapeutic range that could be attributed to
efavirenz and related to its glucuronidation metabolism
and this needs further investigation.
In conclusion, the inflammation caused by hepatitis
viruses B/C infections in the absence of liver function
impairment did not modify efavirenz exposition and no
special indications for TDM are apparently needed in these
patients.
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